Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYTALUX in Gastrointestinal Malignancies
NCT07124351Phase 4Recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of pafolacianine in gastrointestinal cancer, gastric cancer (GC), esophageal cancer, appendiceal cancer, sponsored by Cedars-Sinai Medical Center. Started Sep 2025; status: recruiting.
02
Drugs
pafolacianine
03
Conditions
gastrointestinal cancergastric cancer (GC)esophageal cancerappendiceal cancer
Beyond the preview
Go deeper on NCT07124351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124351.